Literature DB >> 16733217

Frequent loss of heterozygosity at 6q in pheochromocytoma.

Sebsebe Lemeta1, Kaisa Salmenkivi, Lea Pylkkänen, Markku Sainio, Sirkku T Saarikoski, Johanna Arola, Päivi Heikkilä, Caj Haglund, Kirsti Husgafvel-Pursiainen, Tom Böhling.   

Abstract

Multiple genetic alterations have been associated with pheochromocytoma (PCC). Most PCCs are sporadic, but they also occur in inherited tumor syndromes, including von Hippel-Lindau disease. Although the etiology of most inherited PCCs is well documented, little is known about the etiology of sporadic tumors. Mutations of those genes that harbor germ-line mutations in familial cases cover only 10% to 15% of somatic mutations in sporadic PCCs. A previous cytogenetic analysis indicated frequent loss of 6q in sporadic PCCs. We therefore investigated in detail 18 PCCs using 22 microsatellite markers spanning 6q to search for the presence of allele deletions and identify specific regions likely to contain tumor suppressor genes involved in PCC. Moreover, we sought to compare PCC with capillary hemangioblastoma, another von Hippel-Lindau disease-associated tumor that we previously found to harbor frequent loss of heterozygosity (LOH) at 6q. Our study revealed a high frequency (13/18; 72%) of overall 6q LOH in PCCs. Loss of heterozygosity at 6q was observed in 6 benign (6/9; 67%) and 7 borderline (7/9; 78%) tumors. We identified 2 regions where LOH or allelic imbalance was common (ie, 6q14 [9/18; 50%] and 6q23-24 [6/18; 33%]). We further focused the search using markers specific for the ZAC1 gene region located at 6q24-25. Altogether, for all 6q23-25 markers, including the ZAC1-specific ones, LOH or allelic imbalance was observed in 50% (9/18) of the PCCs. Similar to our findings for capillary hemangioblastomas, our data for the first time suggest that one or several tumor suppressor genes located at 6q, particularly at 6q23-24, may play a role in the tumorigenesis of PCCs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16733217     DOI: 10.1016/j.humpath.2006.02.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Molecular cytogenetic characterization in four pediatric pheochromocytomas and paragangliomas.

Authors:  Ales Vicha; Milena Holzerova; Anna Krepelova; Zdenek Musil; Pavel Prochazka; David Sumerauer; Roman Kodet; Tomas Eckschlager; Marie Jarosova
Journal:  Pathol Oncol Res       Date:  2011-04-05       Impact factor: 3.201

2.  Overexpression of SASH1 related to the decreased invasion ability of human glioma U251 cells.

Authors:  Liu Yang; Mei Liu; Zhikai Gu; Jianguo Chen; Yaohua Yan; Jian Li
Journal:  Tumour Biol       Date:  2012-08-23

3.  SASH1 regulates proliferation, apoptosis, and invasion of osteosarcoma cell.

Authors:  Qingbing Meng; Minqian Zheng; Hongbing Liu; Changzhi Song; Wensheng Zhang; Juan Yan; Ling Qin; Xiaolan Liu
Journal:  Mol Cell Biochem       Date:  2012-10-29       Impact factor: 3.396

4.  Lot1 is a key element of the pituitary adenylate cyclase-activating polypeptide (PACAP)/cyclic AMP pathway that negatively regulates neuronal precursor proliferation.

Authors:  Tatiana Fila; Stefania Trazzi; Christophe Crochemore; Renata Bartesaghi; Elisabetta Ciani
Journal:  J Biol Chem       Date:  2009-04-03       Impact factor: 5.157

Review 5.  The VHL/HIF axis in clear cell renal carcinoma.

Authors:  Chuan Shen; William G Kaelin
Journal:  Semin Cancer Biol       Date:  2012-06-13       Impact factor: 15.707

6.  Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene.

Authors:  Chuan Shen; Rameen Beroukhim; Steven E Schumacher; Jing Zhou; Michelle Chang; Sabina Signoretti; William G Kaelin
Journal:  Cancer Discov       Date:  2011-06-07       Impact factor: 39.397

7.  PLAGL1 gene function during hepatoma cells proliferation.

Authors:  Ana F Vega-Benedetti; Cinthia N Saucedo; Patrizia Zavattari; Roberta Vanni; Felix Royo; Francisco Llavero; José L Zugaza; Luis A Parada
Journal:  Oncotarget       Date:  2018-08-28

8.  ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.

Authors:  Leonardo Vieria Neto; Luiz Eduardo Wildemberg; Leandro Machado Colli; Leandro Kasuki; Nelma Veronica Marques; Aline Barbosa Moraes; Emerson L Gasparetto; Christina Maeda Takiya; Margaret Castro; Mônica Roberto Gadelha
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

9.  Composite tumor with pheochromocytoma and immature neuroblastoma: report of two cases with cytogenetic analysis and discussion of current terminology.

Authors:  Lily Tran; Carrie Fitzpatrick; Susan L Cohn; Peter Pytel
Journal:  Virchows Arch       Date:  2017-09-01       Impact factor: 4.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.